$CPMV
Mosaic ImmunoEngineering Inc. Stock $cpmv

$cpmv Overview Financials Valuation SEC Filings Company Website

2023 Q1 Form 10-K Financial Statement

#000168316823001237 Filed on March 02, 2023

Income Statement

Concept	2023 Q1	2022 Q4	2022
Revenue	$0.00	$0.00	$0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$281.9K	$290.5K	$1.579M
YoY Change	-29.77%	-32.7%	-22.79%
% of Gross Profit
Research & Development	$177.9K	$207.0K	$1.048M
YoY Change	-45.71%	-47.36%	-28.0%
% of Gross Profit
Depreciation & Amortization
YoY Change
% of Gross Profit
Operating Expenses	$459.8K	$497.6K	$2.628M
YoY Change	-36.93%	-39.69%	-24.95%
Operating Profit	-$459.8K		-$2.628M
YoY Change	-36.93%		-24.95%
Interest Expense	-$13.87K	-$36.55K	-$93.95K
YoY Change	-59.74%	44.41%	-48.07%
% of Operating Profit
Other Income/Expense, Net	$63.13K	$0.00	$249.1K
YoY Change	-283.26%		-237.66%
Pretax Income	-$396.6K	-$534.1K	-$2.378M
YoY Change	-48.05%	-37.18%	-35.4%
Income Tax	$2.400K	$0.00	$2.400K
% Of Pretax Income
Net Earnings	-$399.0K	-$534.1K	-$2.381M
YoY Change	-47.73%	-37.18%	-35.38%
Net Earnings / Revenue
Basic Earnings Per Share	-$0.06		-$0.33
Diluted Earnings Per Share	-$0.06	-$0.07	-$0.33
COMMON SHARES
Basic Shares Outstanding	7.242M shares	7.241M shares	7.236M shares
Diluted Shares Outstanding	7.236M shares		7.236M shares

Balance Sheet

Concept	2023 Q1	2022 Q4	2022
SHORT-TERM ASSETS
Cash & Short-Term Investments	$125.8K	$220.7K	$220.7K
YoY Change	-66.73%	-2.43%	-2.43%
Cash & Equivalents	$125.8K	$220.6K	$220.7K
Short-Term Investments
Other Short-Term Assets	$22.69K	$40.63K	$40.63K
YoY Change	-11.16%	-6.27%	-6.27%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets	$148.5K	$261.3K	$261.3K
YoY Change	-63.21%	-3.05%	-3.05%
LONG-TERM ASSETS
Property, Plant & Equipment
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets	$0.00	$0.00	$0.00
YoY Change
TOTAL ASSETS
Total Short-Term Assets	$148.5K	$261.3K	$261.3K
Total Long-Term Assets	$0.00	$0.00	$0.00
Total Assets	$148.5K	$261.3K	$261.3K
YoY Change	-63.21%	-3.05%	-3.05%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$127.9K	$133.5K	$133.5K
YoY Change	-4.11%	17.58%	17.58%
Accrued Expenses	$601.7K	$584.8K	$3.560M
YoY Change	-73.85%	-19.25%	83.68%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$4.172M	$3.918M	$3.918M
YoY Change	53.64%	67.9%	67.9%
LONG-TERM LIABILITIES
Long-Term Debt	$1.255M	$1.228M	$1.228M
YoY Change	12.89%	67.09%	67.09%
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities	$1.255M	$1.228M	$1.228M
YoY Change	12.89%	67.09%	67.09%
TOTAL LIABILITIES
Total Short-Term Liabilities	$4.172M	$3.918M	$3.918M
Total Long-Term Liabilities	$1.255M	$1.228M	$1.228M
Total Liabilities	$5.427M	$5.146M	$5.146M
YoY Change	41.8%	67.7%	67.7%
SHAREHOLDERS EQUITY
Retained Earnings	-$7.307M	-$6.908M
YoY Change		52.59%
Common Stock	$72.00	$72.00
YoY Change		0.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	-$5.278M	-$4.885M	-$4.885M
YoY Change
Total Liabilities & Shareholders Equity	$148.5K	$261.3K	$261.3K
YoY Change	-63.21%	-3.05%	-3.05%

Cashflow Statement

Concept	2023 Q1	2022 Q4	2022
OPERATING ACTIVITIES
Net Income	-$399.0K	-$534.1K	-$2.381M
YoY Change	-47.73%	-37.18%	-35.38%
Depreciation, Depletion And Amortization
YoY Change
Cash From Operating Activities	-$171.9K	-$163.5K	-$690.1K
YoY Change	-9.41%	-2.09%	1.6%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities	$77.00K	$0.00	$343.0K
YoY Change			1140.96%
Cash From Investing Activities	$77.00K	$0.00	$343.0K
YoY Change			1140.96%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	$0.00	0.000	$341.6K
YoY Change	-100.0%		-34.93%
NET CHANGE
Cash From Operating Activities	-$171.9K	-163.5K	-$690.1K
Cash From Investing Activities	$77.00K	0.000	$343.0K
Cash From Financing Activities	$0.00	0.000	$341.6K
Net Change In Cash	-$94.87K	-163.5K	-$5.497K
YoY Change	-162.45%	-2.09%	-95.66%
FREE CASH FLOW
Cash From Operating Activities	-$171.9K	-$163.5K	-$690.1K
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2022	dei	Entity Central Index Key EntityCentralIndexKey	0000836564
CY2022	dei	Amendment Flag AmendmentFlag	false
CY2022	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2022
CY2022	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2022	us-gaap	Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures		usd
CY2021	cpmv	Conversion Of Series Convertible Voting Preferred Stock ConversionOfSeriesConvertibleVotingPreferredStock		usd
CY2021	us-gaap	Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures		usd
CY2022	dei	Document Type DocumentType	10-K
CY2022	dei	Document Annual Report DocumentAnnualReport	true
CY2022	dei	Document Period End Date DocumentPeriodEndDate	2022-12-31
CY2022	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2022	dei	Document Transition Report DocumentTransitionReport	false
CY2022	dei	Entity File Number EntityFileNumber	0-22182
CY2022	dei	Entity Registrant Name EntityRegistrantName	MOSAIC IMMUNOENGINEERING, INC.
CY2022	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2022	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	84-1070278
CY2022	dei	Entity Address Address Line1 EntityAddressAddressLine1	1537 South Novato Blvd,
CY2022	dei	Entity Address Address Line2 EntityAddressAddressLine2	#5
CY2022	dei	Entity Address City Or Town EntityAddressCityOrTown	Novato
CY2022	dei	Entity Address State Or Province EntityAddressStateOrProvince	CA
CY2022	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	94947
CY2022	dei	City Area Code CityAreaCode	(657)
CY2022	dei	Local Phone Number LocalPhoneNumber	208-0890
CY2022	dei	Security12b Title Security12bTitle	Common Stock, $0.00001 par value
CY2022	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2022	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2022	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2022	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2022	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2022	dei	Entity Small Business EntitySmallBusiness	true
CY2022	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2022	dei	Entity Shell Company EntityShellCompany	false
CY2022Q2	dei	Entity Public Float EntityPublicFloat	1468607	usd
CY2023Q1	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	7242137	shares
CY2022	dei	Auditor Firm AuditorFirmId	170
CY2022	dei	Auditor Name AuditorName	KMJ Corbin & Company LLP
CY2022	dei	Auditor Location AuditorLocation	Irvine, California
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	220645	usd
CY2021Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	226142	usd
CY2022Q4	us-gaap	Prepaid Expense And Other Assets PrepaidExpenseAndOtherAssets	40632	usd
CY2021Q4	us-gaap	Prepaid Expense And Other Assets PrepaidExpenseAndOtherAssets	43352	usd
CY2022Q4	us-gaap	Assets Current AssetsCurrent	261277	usd
CY2021Q4	us-gaap	Assets Current AssetsCurrent	269494	usd
CY2022Q4	us-gaap	Assets Assets	261277	usd
CY2021Q4	us-gaap	Assets Assets	269494	usd
CY2022Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	133464	usd
CY2021Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	113513	usd
CY2022Q4	us-gaap	Derivative Liabilities Current DerivativeLiabilitiesCurrent	46700	usd
CY2021Q4	us-gaap	Derivative Liabilities Current DerivativeLiabilitiesCurrent	104300	usd
CY2022Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	2399132	usd
CY2021Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	1391297	usd
CY2022Q4	cpmv	Accrued Consulting AccruedConsulting	753570	usd
CY2021Q4	cpmv	Accrued Consulting AccruedConsulting	474275	usd
CY2022Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	584808	usd
CY2021Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	249972	usd
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	3917674	usd
CY2021Q4	us-gaap	Liabilities Current LiabilitiesCurrent	2333357	usd
CY2022Q4	us-gaap	Convertible Debt ConvertibleDebt	1228361	usd
CY2021Q4	us-gaap	Convertible Debt ConvertibleDebt	735148	usd
CY2022Q4	us-gaap	Liabilities Liabilities	5146035	usd
CY2021Q4	us-gaap	Liabilities Liabilities	3068505	usd
CY2022Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.00001
CY2021Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.00001
CY2022Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2021Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.00001
CY2021Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.00001
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000	shares
CY2021Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000	shares
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	7242137	shares
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	7242137	shares
CY2021Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	7241137	shares
CY2021Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	7241137	shares
CY2022Q4	us-gaap	Common Stock Value CommonStockValue	72	usd
CY2021Q4	us-gaap	Common Stock Value CommonStockValue	72	usd
CY2022Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	2023271	usd
CY2021Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	1728148	usd
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-6908102	usd
CY2021Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-4527232	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	-4884758	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	-2799011	usd
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	261277	usd
CY2021Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	269494	usd
CY2022	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	1048457	usd
CY2021	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	1456119	usd
CY2022	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	1579065	usd
CY2021	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	2045047	usd
CY2022	us-gaap	Operating Expenses OperatingExpenses	2627522	usd
CY2021	us-gaap	Operating Expenses OperatingExpenses	3501166	usd
CY2022	us-gaap	Operating Income Loss OperatingIncomeLoss	-2627522	usd
CY2021	us-gaap	Operating Income Loss OperatingIncomeLoss	-3501166	usd
CY2022	cpmv	Gain On Redemption Of Preferred Stock Of Holocom GainOnRedemptionOfPreferredStockOfHolocom	343000	usd
CY2021	cpmv	Gain On Redemption Of Preferred Stock Of Holocom GainOnRedemptionOfPreferredStockOfHolocom	0	usd
CY2022	us-gaap	Interest And Other Income InterestAndOtherIncome	33	usd
CY2021	us-gaap	Interest And Other Income InterestAndOtherIncome	36	usd
CY2022	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet	57600	usd
CY2021	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet	-20800	usd
CY2022	us-gaap	Noninterest Expense NoninterestExpense	69738	usd
CY2021	us-gaap	Noninterest Expense NoninterestExpense	30121	usd
CY2022	us-gaap	Accretion Expense AccretionExpense	81843	usd
CY2021	us-gaap	Accretion Expense AccretionExpense	130027	usd
CY2022	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	249052	usd
CY2021	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-180912	usd
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-2378470	usd
CY2021	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-3682078	usd
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	2400	usd
CY2021	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	2400	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-2380870	usd
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-3684478	usd
CY2022	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.33
CY2021	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.55
CY2022	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.33
CY2021	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.55
CY2022	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	7235609	shares
CY2022	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	7235609	shares
CY2021	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	6712675	shares
CY2021	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	6712675	shares
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	-2799011	usd
CY2022	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	295123	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-2380870	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	-4884758	usd
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	-422541	usd
CY2021	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	1308008	usd
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-3684478	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	-2799011	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-2380870	usd
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-3684478	usd
CY2022	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	295123	usd
CY2021	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	1308008	usd
CY2022	cpmv	Gain On Redemption Of Preferred Stock Of Holocom GainOnRedemptionOfPreferredStockOfHolocom	343000	usd
CY2021	cpmv	Gain On Redemption Of Preferred Stock Of Holocom GainOnRedemptionOfPreferredStockOfHolocom	-0	usd
CY2022	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet	57600	usd
CY2021	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet	-20800	usd
CY2022	us-gaap	Noninterest Expense NoninterestExpense	69738	usd
CY2021	us-gaap	Noninterest Expense NoninterestExpense	30121	usd
CY2022	us-gaap	Accretion Expense AccretionExpense	81843	usd
CY2021	us-gaap	Accretion Expense AccretionExpense	130027	usd
CY2022	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-2720	usd
CY2021	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-7997	usd
CY2022	us-gaap	Increase Decrease In Income Taxes IncreaseDecreaseInIncomeTaxes	0	usd
CY2021	us-gaap	Increase Decrease In Income Taxes IncreaseDecreaseInIncomeTaxes	26078	usd
CY2022	us-gaap	Increase Decrease In Other Accounts Payable IncreaseDecreaseInOtherAccountsPayable	19951	usd
CY2021	us-gaap	Increase Decrease In Other Accounts Payable IncreaseDecreaseInOtherAccountsPayable	27499	usd
CY2022	us-gaap	Increase Decrease In Self Insurance Reserve IncreaseDecreaseInSelfInsuranceReserve	1007835	usd
CY2021	us-gaap	Increase Decrease In Self Insurance Reserve IncreaseDecreaseInSelfInsuranceReserve	997866	usd
CY2022	cpmv	Increase Decrease In Accrued Consulting IncreaseDecreaseInAccruedConsulting	279295	usd
CY2021	us-gaap	Increase Decrease In Other Accrued Liabilities IncreaseDecreaseInOtherAccruedLiabilities	22571	usd
CY2022	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-690129	usd
CY2021	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-679236	usd
CY2022	cpmv	Proceeds From Redemption Of Preferred Stock Of Holocom ProceedsFromRedemptionOfPreferredStockOfHolocom	343000	usd
CY2022	us-gaap	Increase Decrease In Other Accrued Liabilities IncreaseDecreaseInOtherAccruedLiabilities	334836	usd
CY2021	cpmv	Proceeds From Redemption Of Preferred Stock Of Holocom ProceedsFromRedemptionOfPreferredStockOfHolocom	0	usd
CY2021	cpmv	Increase Decrease In Accrued Consulting IncreaseDecreaseInAccruedConsulting	434275	usd
CY2022	cpmv	Proceeds From Dissolution Of Affiliate ProceedsFromDissolutionOfAffiliate	0	usd
CY2021	cpmv	Proceeds From Dissolution Of Affiliate ProceedsFromDissolutionOfAffiliate	27637	usd
CY2022	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	343000	usd
CY2021	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	27637	usd
CY2022	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt	341632	usd
CY2021	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt	525003	usd
CY2022	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	341632	usd
CY2021	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	525003	usd
CY2022	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	-5497	usd
CY2021	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	-126596	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	226142	usd
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	352738	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	220645	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	226142	usd
CY2022	cpmv	Conversion Of Series Convertible Voting Preferred Stock To Common Stock ConversionOfSeriesConvertibleVotingPreferredStockToCommonStock	0	usd
CY2021	cpmv	Conversion Of Series Convertible Voting Preferred Stock To Common Stock ConversionOfSeriesConvertibleVotingPreferredStockToCommonStock	64	usd
CY2022	cpmv	Conversion Of Accrued Payable To Founder To Convertible Note ConversionOfAccruedPayableToFounderToConvertibleNote	0	usd
CY2021	cpmv	Conversion Of Accrued Payable To Founder To Convertible Note ConversionOfAccruedPayableToFounderToConvertibleNote	49997	usd
CY2022	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	2400	usd
CY2021	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	2400	usd
CY2022	us-gaap	Interest Paid Net InterestPaidNet	0	usd
CY2021	us-gaap	Interest Paid Net InterestPaidNet	0	usd
CY2022	us-gaap	Nature Of Operations NatureOfOperations	<p id="xdx_809_eus-gaap--NatureOfOperations_zQznYsC48IS4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>1. <span id="xdx_823_z8bsvikeYcqb">Organization and Business</span></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b> </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Mosaic ImmunoEngineering, Inc. (the “Company,” “combined company,” “Mosaic,” “we,” “us,” or “our”), formerly known as Patriot Scientific Corporation, is a corporation organized under Delaware law on March 24, 1992. We are a development-stage biotechnology company focused on advancing and eventually commercializing our proprietary immunotherapy platform technology. Our lead immunotherapy product candidate, MIE-101, is based on a naturally occurring plant virus known as Cowpea mosaic virus (or CPMV) which is believed to be non-infectious in humans and animals. However, because of its virus structure and genetic composition, CPMV elicits a strong immune response when delivered directly into tumors as shown in our preclinical studies. Data from numerous mouse cancer models and in companion dogs with naturally occurring tumors show the ability of intratumoral administration of CPMV to result in anti-tumor effects in treated tumors and systemically at other sites of disease through immune activation. MIE-101 is currently in late-stage preclinical development and our goal is to advance MIE-101 into veterinary studies and into Phase I clinical trials within 18 to 24 months from the date we are able to raise sufficient funding.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company has two wholly owned subsidiaries: Mosaic ImmunoEngineering Development Company (formerly referred to as Private Mosaic in connection with the reverse merger that closed in August 2020), a corporation organized under Delaware law on March 30, 2020 (date of inception) and Patriot Data Solutions Group, Inc., an inactive subsidiary of PTSC.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Liquidity and Management’s Plans</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The accompanying consolidated financial statements have been prepared assuming the Company will continue as a going concern. At December 31, 2022, the Company had cash and cash equivalents of $<span id="xdx_907_eus-gaap--CashAndCashEquivalentsAtCarryingValue_iI_pp0p0_c20221231_zqwpU1p6uyB6" title="Cash and cash equivalents">220,645</span> and has not yet generated any revenue. Therefore, our ability to continue our operations is highly dependent on our ability to raise capital to fund future operations. We anticipate, based on currently proposed plans and assumptions that our cash and cash equivalents on hand will not satisfy our operational and capital requirements through twelve months from the filing date of this Annual Report on Form 10-K.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">There are a number of uncertainties associated with our ability to raise additional capital and we have no current arrangements with respect to any additional financing. In addition, the continuation of disruptions caused by COVID-19, broad-based inflation, and various economic indicators that the United States economy may be entering a recession in upcoming quarters may cause investors to slow down or delay their decision to deploy capital which will adversely impact our ability to fund future operations. Consequently, there can be no assurance that any additional financing on commercially reasonable terms, or at all, will be available when needed. The inability to obtain additional capital will delay our ability to conduct our business operations. Any additional equity financing may involve substantial dilution to our then existing stockholders. The above matters raise substantial doubt regarding our ability to continue as a going concern.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b> </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"/>
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	220645	usd
CY2022	us-gaap	Prior Period Reclassification Adjustment Description PriorPeriodReclassificationAdjustmentDescription	<p id="xdx_840_eus-gaap--PriorPeriodReclassificationAdjustmentDescription_zccengGt2jMf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><span id="xdx_86F_zA9HjUg2Jxa2">Reclassifications</span></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Certain reclassifications have been made to amounts in the prior year to conform to the current year presentation. All reclassifications have been applied consistently to the periods presented. Such reclassifications have no effect on net loss as previously reported.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b> </b></p>
CY2021	us-gaap	Operating Lease Expense OperatingLeaseExpense	0	usd
CY2022Q4	cpmv	Accrued Consulting Fees AccruedConsultingFees	238000	usd
CY2021Q4	cpmv	Accrued Consulting Fees AccruedConsultingFees	137500	usd
CY2022	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<p id="xdx_841_eus-gaap--ConcentrationRiskCreditRisk_zmgjLH4YxFRe" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><span id="xdx_865_ztNBQF98NxVb">Financial Instruments and Concentrations of Credit Risk</span></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Financial instruments that potentially subject us to concentrations of credit risk consist principally of cash and cash equivalents.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We invest our cash and cash equivalents primarily in money market funds. Cash and cash equivalents are maintained with high quality financial institutions, which are regularly monitored by management. At times, deposits held with financial institutions may exceed the amount of insurance provided by the Federal Deposit Insurance Corporation and the Securities Investor Protection Corporation. We perform ongoing evaluations of these financial institutions to limit our concentration of risk exposure.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p>
CY2022	us-gaap	Use Of Estimates UseOfEstimates	<p id="xdx_843_eus-gaap--UseOfEstimates_zPu6LtLI1qqe" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><span id="xdx_869_zxKgus5Jflsg">Use of Estimates</span></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The preparation of consolidated financial statements in accordance with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. Significant estimates in these consolidated financial statements include those related to the fair value of the anti-dilution issuance rights liability (derivative liability), the timing of conversion of the convertible notes, the provision or benefit for income taxes and the corresponding valuation allowance on deferred tax assets. In addition, management’s assessment of the Company’s ability to continue as a going concern involves the estimation of the amount and timing of future cash inflows and outflows. On an ongoing basis, the Company evaluates its estimates, judgments, and methodologies. The Company bases its estimates on historical experience and on various other assumptions believed to be reasonable. Due to the inherent uncertainty involved in making such accounting estimates and assumptions, the actual financial statement results could differ materially from such accounting estimates and assumptions.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p>
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	0	shares
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	0	shares
CY2022	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	2235962	shares
CY2021	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	1921050	shares
CY2022Q4	us-gaap	Assets Fair Value Disclosure AssetsFairValueDisclosure	220645	usd
CY2022Q4	us-gaap	Liabilities Fair Value Disclosure LiabilitiesFairValueDisclosure	46700	usd
CY2021Q4	us-gaap	Assets Fair Value Disclosure AssetsFairValueDisclosure	226142	usd
CY2021Q4	us-gaap	Liabilities Fair Value Disclosure LiabilitiesFairValueDisclosure	104300	usd
CY2022Q4	us-gaap	Derivative Liabilities Current DerivativeLiabilitiesCurrent	46700	usd
CY2021Q4	us-gaap	Derivative Liabilities Current DerivativeLiabilitiesCurrent	104300	usd
CY2022Q4	us-gaap	Share Price SharePrice	0.99
CY2021Q4	us-gaap	Share Price SharePrice	1.02
CY2022	cpmv	Estimated Additional Shares Of Common Stock EstimatedAdditionalSharesOfCommonStock	71511	shares
CY2021	cpmv	Estimated Additional Shares Of Common Stock EstimatedAdditionalSharesOfCommonStock	134229	shares
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	1.30	pure
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	1.05	pure
CY2022	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P0Y3M
CY2021	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P0Y3M
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.0442	pure
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.0006	pure
CY2022Q4	us-gaap	Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Contingent Liability BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedContingentLiability	177244	usd
CY2021Q4	us-gaap	Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Contingent Liability BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedContingentLiability	177244	usd
CY2022Q4	cpmv	Accrued Patent Expenses AccruedPatentExpenses	382207	usd
CY2021Q4	cpmv	Accrued Patent Expenses AccruedPatentExpenses	41585	usd
CY2022Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	25357	usd
CY2021Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	31143	usd
CY2022Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	584808	usd
CY2021Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	249972	usd
CY2022Q4	us-gaap	Convertible Long Term Notes Payable ConvertibleLongTermNotesPayable	916632	usd
CY2022Q4	cpmv	Convertible Notes Redemption Value ConvertibleNotesRedemptionValue	1145790	usd
CY2022	us-gaap	Share Based Compensation ShareBasedCompensation	295123	usd
CY2021	us-gaap	Share Based Compensation ShareBasedCompensation	1308008	usd
CY2022	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	0	usd
CY2021	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	0	usd
CY2022	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	2400	usd
CY2021	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	2400	usd
CY2022	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	2400	usd
CY2021	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	2400	usd
CY2022	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	0	usd
CY2021	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	0	usd
CY2022	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	0	usd
CY2021	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	0	usd
CY2022	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	0	usd
CY2021	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	0	usd
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	2400	usd
CY2021	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	2400	usd
CY2022	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.2100	pure
CY2021	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.2100	pure
CY2022	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	-0.0008	pure
CY2021	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	-0.0005	pure
CY2022	cpmv	Fair Market Value Of Derivative Liability FairMarketValueOfDerivativeLiability	0.0051	pure
CY2021	cpmv	Fair Market Value Of Derivative Liability FairMarketValueOfDerivativeLiability	-0.0012	pure
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments	-0.0072	pure
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments	-0.0089	pure
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.2081	pure
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.2000	pure
CY2022	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	-0.0010	pure
CY2021	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	-0.0006	pure
CY2022Q4	us-gaap	Deferred Tax Assets State Taxes DeferredTaxAssetsStateTaxes	504	usd
CY2021Q4	us-gaap	Deferred Tax Assets State Taxes DeferredTaxAssetsStateTaxes	504	usd
CY2022Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities	953175	usd
CY2021Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities	554125	usd
CY2022Q4	us-gaap	Deferred Tax Assets Investments DeferredTaxAssetsInvestments	6701	usd
CY2021Q4	us-gaap	Deferred Tax Assets Investments DeferredTaxAssetsInvestments	22620	usd
CY2022Q4	us-gaap	Deferred Tax Assets Property Plant And Equipment DeferredTaxAssetsPropertyPlantAndEquipment	0	usd
CY2021Q4	us-gaap	Deferred Tax Assets Property Plant And Equipment DeferredTaxAssetsPropertyPlantAndEquipment	7	usd
CY2022Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits	478274	usd
CY2021Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits	384903	usd
CY2022Q4	us-gaap	Deferred Income Taxes And Other Tax Receivable Current DeferredIncomeTaxesAndOtherTaxReceivableCurrent	215261	usd
CY2021Q4	us-gaap	Deferred Income Taxes And Other Tax Receivable Current DeferredIncomeTaxesAndOtherTaxReceivableCurrent	231180	usd
CY2022Q4	us-gaap	Deferred Tax Assets In Process Research And Development DeferredTaxAssetsInProcessResearchAndDevelopment	83744	usd
CY2021Q4	us-gaap	Deferred Tax Assets In Process Research And Development DeferredTaxAssetsInProcessResearchAndDevelopment	0	usd
CY2022Q4	cpmv	Deferred Tax Assets Limited Net Operating Loss Carryforwards DeferredTaxAssetsLimitedNetOperatingLossCarryforwards	597262	usd
CY2021Q4	cpmv	Deferred Tax Assets Limited Net Operating Loss Carryforwards DeferredTaxAssetsLimitedNetOperatingLossCarryforwards	597262	usd
CY2022Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	504945	usd
CY2021Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	372512	usd
CY2022Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	2826464	usd
CY2021Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	2117873	usd
CY2022Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	0	usd
CY2021Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	0	usd
CY2022	us-gaap	Operating Lease Expense OperatingLeaseExpense	0	usd

Files In Submission

Name	View Source	Status
FilingSummary.xml	Edgar Link	unprocessable
cpmv-20221231_cal.xml	Edgar Link	unprocessable
cpmv-20221231_def.xml	Edgar Link	unprocessable
0001683168-23-001237-index-headers.html	Edgar Link	pending
0001683168-23-001237-index.html	Edgar Link	pending
0001683168-23-001237.txt	Edgar Link	pending
0001683168-23-001237-xbrl.zip	Edgar Link	pending
cpmv-20221231.xsd	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
mosaic_ex2101.htm	Edgar Link	pending
mosaic_ex2301.htm	Edgar Link	pending
mosaic_ex3101.htm	Edgar Link	pending
mosaic_ex3102.htm	Edgar Link	pending
mosaic_ex3201.htm	Edgar Link	pending
mosaic_ex3202.htm	Edgar Link	pending
mosaic_i10k-123122.htm	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
cpmv-20221231_pre.xml	Edgar Link	unprocessable
cpmv-20221231_lab.xml	Edgar Link	unprocessable
mosaic_i10k-123122_htm.xml	Edgar Link	completed
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$CPMV
Mosaic ImmunoEngineering Inc. Stock $cpmv

2023 Q1 Form 10-K Financial Statement

#000168316823001237 Filed on March 02, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$CPMV Mosaic ImmunoEngineering Inc. Stock $cpmv

2023 Q1 Form 10-K Financial Statement

#000168316823001237 Filed on March 02, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$CPMV
Mosaic ImmunoEngineering Inc. Stock $cpmv